Cannabis-Music Pairing Cuts Prescription Use, NIH-Funded Study Finds

Study Design and Patient Cohort

Researchers enrolled 240 adults with chronic pain or generalized anxiety disorder across three study arms over 12 weeks. Participants were randomized into cannabis-only, music-therapy-only, or combined-modality groups. The cannabis cohort used standardized flower (18-22% THC, <1% CBD) via vaporization three times weekly. Music group members attended biweekly guided listening sessions featuring 432 Hz tuning and binaural beats. The combination arm received both interventions.

All participants maintained symptom diaries and underwent monthly blood panels to track inflammatory biomarkers. Patients with active substance use disorders were excluded. So were those taking opioids, benzodiazepines, or SSRIs at baseline.

Prescription Drug Reduction in Combination Group

Patients using both cannabis and music reduced prescription analgesic and anxiolytic use by 47% at week 12, compared to 22% in the cannabis-only arm. The combination group reported a median 3.2-point drop on the Visual Analog Scale for pain, versus 1.8 points for cannabis alone. Anxiety scores measured by the GAD-7 instrument fell 6.1 points in the dual-modality cohort—nearly double the cannabis-only decline of 3.4 points.

Twelve participants in the combination arm discontinued all prescription medications by study end, compared to three in the cannabis-only group. No serious adverse events were recorded in any arm.

Cannabinoid-Terpene Interaction With Auditory Stimuli

The study's secondary analysis found elevated anandamide levels in patients exposed to both cannabis and music, suggesting enhanced endocannabinoid tone. Researchers think rhythmic auditory input may upregulate CB1 receptor expression in the amygdala and prefrontal cortex, regions dense with cannabinoid binding sites. Terpene profiles in the study flower—dominated by myrcene (1.2%), limonene (0.8%), and beta-caryophyllene (0.6%)—may have interacted with dopaminergic pathways activated during music listening.

Lead investigator Dr. Yael Brenner noted that the 432 Hz frequency used in sessions has been associated with parasympathetic nervous system activation in prior trials. She cautioned against overstating mechanistic certainty, though. "We're observing a synergy, but the neurochemical cascade isn't fully mapped yet," Brenner said in the published discussion.

The data suggest that multimodal interventions using the endocannabinoid system and auditory processing networks may offer a pathway to reduce pharmaceutical dependence in treatment-resistant populations.

Emotional Regulation and Quality-of-Life Metrics

Combination-group participants scored 8.3 points higher on the WHO Quality of Life-BREF instrument at week 12 compared to baseline. Subscales measuring psychological health and social relationships showed the steepest gains. The cannabis-only arm improved by 4.1 points, and the music-only arm by 3.7 points, suggesting additive rather than purely synergistic effects in some domains.

Emotional dysregulation, assessed via the Difficulties in Emotion Regulation Scale, declined 41% in the dual-modality group versus 19% for cannabis alone. Music therapy's structured processing of affective states may complement cannabis's anxiolytic properties without the sedation or cognitive blunting reported by some monotherapy users, researchers said.

Implications for Integrative Medicine Protocols

The findings arrive as 38 states have legalized medical cannabis, yet few clinical guidelines address adjunctive therapies. Brenner's team recommends pilot programs pairing dispensary access with referrals to certified music therapists, particularly in states with chronic pain or PTSD as qualifying conditions. The study's protocol—vaporized flower at 0.1-0.15 g per session, paired with 45-minute guided listening—could serve as a template for integrative pain clinics.

For background on the evolving evidence base, see the CannIntel topic hub on cannabis medical research. Phase two will examine dose-response curves and strain-specific terpene profiles to refine therapeutic windows.

The research team is now recruiting for a follow-up study comparing live music performance to recorded sessions, hypothesizing that social co-regulation may amplify outcomes. Results are expected in Q2 2027.